1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Triple Analysis: Breast Cancer, Colorectal Cancer and Prostate Cancer

This triple analysis focuses on cancer drug development strategies in Breast Cancer, Colorectal Cancer and Prostate Cancer. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Breast Cancer
The breast cancer drug report part comprises defined and up to date development strategies for 470 drugs within the portfolio of 247 companies world-wide, from Ceased to Marketed. The report extensively analyses their 234 identified drug targets, organized into 223 drug target strategies, and assesses them in breast cancer drug development.
This part is based on the following publication:
Commercializing Breast Cancer Drugs: The Faster Route to Consider Your Options and Position of Others

Part II: Colorectal Cancer
The colorectal cancer report part comprises defined and up to date development strategies for 347 colorectal cancer drugs within the portfolio of 182 investigators, from Ceased to Marketed. This part extensively analyses their 210 identified drug targets, organized into 205 drug target strategies, and assesses them in eight different compound strategies in colorectal cancer.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Colorectal Cancer Pipeline: From Research and Development to Market

Part III: Prostate Cancer
The prostate cancer drug report part comprises defined and up to date development strategies for 394 drugs within the portfolio of 222 companies world-wide, from Ceased to Marketed. The report extensively analyses their 227 identified drug targets, organized into 216 drug target strategies, and assesses them in breast cancer drug development.
This part is based on the following publication:
Competitive Handbook towards Personalized Medicine in Prostate Cancer

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Table Of Contents

Triple Analysis: Breast Cancer, Colorectal Cancer and Prostate Cancer
Key Topics Covered:

Part I: Breast Cancer
5.1 The Scope of this Report 32
6 Consider the Therapeutic Target Among Breast Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (234 Drug Targets) 36-522
7 Emerging New Products to Established Ones: Drug Target Strategies of Breast Cancer Drugs by their Highest Stage of Development (223 Drug Target Strategies and 470 Drugs) 523-797
8 Compound Strategies at Work: Competitive Benchmarking of Breast Cancer Drugs by Compound Strategy (8 Compound Strategies) 798-850
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Breast Cancer Drug Pipeline by Investigator (247 Investigators and 470 Drugs) 851-1723
10 Disclaimer 1724
Figures: Includes 8 Figures
Tables: Includes 309 Tables
Total Number of Pages: 1,755

Part II: Colorectal Cancer
5.1 The Scope of this Report 28
6 Consider the Therapeutic Target Among Colorectal Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (210 Drug Targets) 32-451
7 Emerging New Products to Established Ones: Drug Target Strategies of Colorectal Cancer Drugs by their Highest Stage of Development (205 Drug Target Strategies and 347 Colorectal Cancer Drugs) 452-699
8 Compound Strategies at Work: Competitive Benchmarking of Colorectal Cancer Drugs by Compound Strategy (8 Compound Strategies) 700-745
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Colorectal Cancer Drug Pipeline by Investigator (182 Companies) 746-1,039
10 Disclaimer 1040
11 Drug Index 1041
12 Company Index 1050
Figures: Includes 6 Figures
Tables: Includes 242 Tables
Total Number of Pages: 1,056

Part III: Prostate Cancer
5.1 The Scope of this Report 31
6 Consider the Therapeutic Target Among Prostate Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (227 Drug Targets) 35-437
7 Emerging New Products to Established Ones: Drug Target Strategies of Prostate Cancer Drugs by their Highest Stage of Development (216 Drug Target Strategies and 394 Drugs) 438-699
8 Compound Strategies at Work: Competitive Benchmarking of Prostate Cancer Drugs by Compound Strategy (8 Compound Strategies) 700-748
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Prostate Cancer Drug Pipeline by Investigator (222 Investigators and 394 Drugs) 749-1470
10 Disclaimer 1471
Figures: Includes 8 Figures
Tables: Includes 283 Tables
Total Number of Pages: 1,493

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Papillary Thyroid Cancer - Pipeline Review, H1 2016

Papillary Thyroid Cancer - Pipeline Review, H1 2016

  • $ 2 000
  • Company report
  • April 2016
  • by Global Markets Direct

Papillary Thyroid Cancer - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Papillary Thyroid Cancer - Pipeline Review, H1 2016’, provides an overview of the Papillary Thyroid Cancer pipeline ...

Metastatic Colorectal Cancer - Pipeline Review, H1 2016

Metastatic Colorectal Cancer - Pipeline Review, H1 2016

  • $ 2 000
  • Company report
  • May 2016
  • by Global Markets Direct

Metastatic Colorectal Cancer - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Metastatic Colorectal Cancer - Pipeline Review, H1 2016’, provides an overview of the Metastatic Colorectal ...

Quest Diagnostics Incorporated (DGX) - Product Pipeline Analysis, 2016 Update

Quest Diagnostics Incorporated (DGX) - Product Pipeline Analysis, 2016 Update

  • $ 750
  • Company report
  • March 2016
  • by Global Data

Summary Quest Diagnostics Incorporated (Quest Diagnostics) is a provider of diagnostic information services to patients and physicians through a chain of laboratories and company-owned patient service ...


Download Unlimited Documents from Trusted Public Sources

Biosceptre - Company Report, July 2016

  • July 2016
    52 pages
  • Therapy  

    Cancer  

    Targeted Therap...  

  • United States  

View report >

Oncimmune Ltd - Investor Report, July 2016

  • July 2016
    33 pages
  • Cancer  

    Lung Cancer  

    Cancer Diagnost...  

  • United States  

    World  

View report >

RedHill Biopharma Ltd. - Company Report, July 2016

  • July 2016
    60 pages
  • Therapy  

    Cancer  

    Digestive Syste...  

  • United States  

    Europe  

    World  

View report >

ref:plp2012

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.